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Abstract: 
 
Objective: Cardiopulmonary exercise testing (CPET) is used to predict outcome in patients 
with mild-to-moderate heart failure (HF). Single CPET-derived variables are often used, but 
we wanted to see if a composite score achieved better predictive power. 
Methods: Retrospective analysis of patient records at the Department of Cardiology, Castle 
Hill Hospital, Kingston-upon-Hull. 387 patients [median (25
th
-75
th
 percentile)] [age 65 (56-
72) years; 79% males; LVEF 34 (31-37) %] were included. Patients underwent a symptom-
limited, maximal CPET on a treadmill. During a median follow up of 8.6 ± 2.1 years in 
survivors, 107 patients died. Survival models were built and validated using a hybrid 
approach between the bootstrap and Cox regression. Nine CPET-derived variables were 
included. Z-score defined each variable's predictive strength. Model coefficients were 
converted to a risk score. 
Results: Four CPET-related variables were independent predictors of all-cause mortality in 
the survival model: the presence of exertional oscillatory ventilation (EOV), increasing slope 
of the relation between ventilation and carbon dioxide production (VE/VCO2 slope), 
decreasing oxygen uptake efficiency slope (OUES), and an increase in the lowest ventilatory 
equivalent for carbon dioxide (VEqCO2 nadir). Individual predictors of mortality ranged from 
0.60 to 0.71 using Harrell’s C-statistic, but the optimal combination of EOV + VE/VCO2 slope 
+ OUES + VEqCO2 nadir reached 0.75. The Hull CPET risk score had a significantly higher area 
under the curve (0.78) when compared to the Heart Failure Survival Score (AUC=0.70; 
P<0.001). 
Conclusions: A composite risk score using variables from CPET out-performs the traditional 
single variable approach in predicting outcome in patients with mild-to-moderate HF.  
 
Keywords: CPET score, prognosis, risk, CHF, exercise, EOV, OUES 
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What is already known about this subject? 
There is a substantial literature describing the performance of different variables derived 
from cardiopulmonary exercise testing (CPET) as predictors of prognosis. Optimal cut-points 
delineating higher risk patients are often identified using binary statistical approaches. 
However, the traditional approach often focuses on the top performing variable(s) whilst 
discou ting the additive or cumulative effect of a combination of different predictor 
variables. Composite risk scores, which combine the level of risk across a number of 
variables, have become increasingly prevalent especially in studies including patients with 
heart failure (HF). 
 
What does this study add? 
None of the composite approaches to risk scores derived by CPET have combined both 
conventional variables, such as peak VO2 and VE/VCO2 slope, and more recently described 
variables, such as the presence of exertional oscillatory ventilation, VEqCO2 nadir, peak 
circulatory power and oxygen uptake efficiency slope. We have developed a composite risk 
model derived from CPET-related variables (traditional and contemporary) to predict 
mortality in patients with mild-to-moderate HF. Our model derived from CPET-only variables 
outperformed the Heart Failure Survival Score. 
 
How might this impact on clinical practice? 
Clinicians should consider using composite risk scores from CPET studies to improve risk 
prediction in patients with mild-to-moderate heart failure. 
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Introduction: 
 
Chronic heart failure (HF) is very common and has a poor prognosis despite medical 
therapy.(1) The patient’s performance during a cardio-pulmonary exercise test (CPET) is 
used to assess prognosis and to help select patients who might benefit from heart 
transplantation. CPET broadly provides two types of prognostic variable: a measure of 
exercise capacity, such as peak oxygen consumption (VO2) or peak circulatory power 
(markers of oxygen delivery and extraction), and a measure of the ventilatory response to 
exercise, such as the slope of the relation between ventilation and carbon dioxide 
production (VE/VCO2 slope), reflecting the abnormal stimulus to ventilation in HF.(2)  
 
There is a large literature describing the performance of different variables derived from 
CPET as predictors of prognosis. Optimal cut-points delineating higher risk patients are often 
identified using binary statistical approaches. However, the traditional approach often 
focuses on the top performing variable(s) whilst discounting the additive or cumulative 
effect of a combination of different predictor variables.(3) Composite risk scores, which 
combine the level of risk across a number of variables, have become more commonplace.(3-
5) None of the composite approaches has combined both conventional variables, such as 
peak VO2 and VE/VCO2 slope, and more recently described variables, such as the presence 
of exertional oscillatory ventilation, peak circulatory power and oxygen uptake efficiency 
slope. We aimed to develop a composite risk model derived from CPET-related variables to 
predict mortality in patients with mild-to-moderate HF.  
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Methods: 
The Hull and East Riding Ethics Committee approved the study,
 
and all patients provided 
informed consent. We recruited consecutive patients referred to a community heart failure 
clinic with symptoms of breathlessness (NYHA functional class II-III) who had left ventricular 
systolic dysfunction on investigation. Clinical information obtained included past medical 
history and drug and smoking history. Clinical examination included measurement of body 
mass index (BMI), heart rate, rhythm, and blood pressure. Patients were excluded
 
if they 
were unable to exercise because of non-cardiac limitations (such as osteoarthritis), or had 
significant respiratory disease (defined as a predicted FEV1/FVC <70%).   
 
Heart failure was defined as the presence of current symptoms of HF, or a history of 
symptoms controlled by ongoing therapy, and impaired left ventricular systolic function.
 
Left 
ventricular function was assessed by estimation on a scale of normal, mild, mild-to-
moderate, moderate, moderate-to-severe, and severe impairment using echocardiography. 
Left ventricular ejection fraction (LVEF) was calculated using the Simpson’s formula from 
measurements of end-diastolic and end-systolic volumes on apical 2D views where possible, 
and LVSD was diagnosed if LVEF was ≤45%. When LVEF could not be calculated, LVSD was 
diagnosed if there was at least “mild-to-moderate” impairment.  
 
Patients underwent a symptom-limited, maximal CPET on a treadmill using the Bruce 
protocol modified by the addition of a Stage 0 (2.74 km·h
-1
 and 0% gradient) at the onset of 
exercise. Metabolic gas exchange was measured with an Oxycon Delta metabolic cart 
(VIASYS Healthcare Inc., Philadelphia, PA). Prior to start of CPET, patients rested in a seated 
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position and resting end-tidal CO2 (resting PETCO2) was averaged over the first two 
minutes.(6)  
To develop the composite risk score, we focused on variables that have previously been 
identified as independent predictors of mortality in patients with HF: 
• Exercise oscillatory ventilation (EOV) during CPET using the criteria described by 
Leite and colleagues.(7) The criteria included: (a) at least three oscillatory 
fluctuations in minute ventilation during warm-up and exercise; (b) regular 
oscillations, as defined by a standard deviation of 3 consecutive cycles (time 
between 2 consecutive nadirs) within 20% of the average; (c) a minimal average 
ventilation amplitude of at least 5 litres, defined as peak VE of one oscillation minus 
the average of two adjacent nadirs.(8)  
• Peak oxygen uptake (peak VO2) was calculated as the average VO2 for the final 30s of 
exercise.  
• Peak circulatory power (PCP) was defined as the product of peak VO2 and peak 
systolic arterial pressure at peak exercise intensity.(9)  
• The oxygen uptake efficiency slope (OUES) was derived from the linear relationship 
between oxygen consumption (VO2) and log10 ventilation (VE).(10)  
• The ventilatory anaerobic threshold (AT) was calculated by the V-slope method.(11) 
• The gradient of the relationship between VE and VCO2 (VE/VCO2 slope) was 
calculated by linear regression analysis using data acquired from the whole test.  
• The lowest point of the relation between ventilation and carbon dioxide production 
(VEqCO2 nadir) was identified by plotting the consecutive 30-second readings of the 
data.(12, 13)  
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• The peak respiratory exchange ratio (pRER) was calculated as the mean VCO2/VO2 
ratio for the final 30s of exercise.   
• Heart rate reserve (HRR) was calculated as the difference between resting heart rate 
and peak heart rate achieved during the CPET.   
 
Statistical Methodology 
Continuous data are summarised by the median (25
th
 to 75th percentile ranges); categorical 
data by percentages. The primary outcome measure was all-cause mortality. Models were 
built and validated using a hybrid approach between the bootstrap and Cox regression.(14) 
We have used the method in previous work.(15) Bootstrapping is sampling data with 
replacement meaning that an individual may be selected more than once per bootstrapped 
sample.(16) There should be no more than 200 bootstraps per sample,(17) and the method is 
not without its critics.(18) However, Sauerbrei (14) contended that with respect to bootstrap 
sampling, key variables will be included in most replications, and the inclusion frequency may 
be used as a criterion for the importance of a variable. To test the adequacy of the model we 
generated 10 test samples using 10-fold cross-validation. The data was split into 10 equal sub-
samples (S1-S10) at random. From this we generated 10 test samples leaving out 10% of the 
data at a time. Thus, test sample 1 was generated leaving out sub-sample S1 and so on. 
Royston (19) recently developed a new measure of explained variance for use with censored 
survival data which was applied to the test samples.   
 
Nine CPET-derived variables were included: EOV, OUES, VEqCO2 nadir, VE/VCO2 slope, 
resting PETCO2, peak VO2, HRR, AT, and PCP. Optimal binary cut-points were calculated from 
receiver operating characteristic (ROC) curves. The cut-offs were determined by maximising 
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the sum of sensitivity and specificity (equivalent to the Youden index).  ROC curves were 
drawn using methods of Hanley and McNeil.(20) 
 
Goodness-of-fit was explored by Cox-Snell residuals. We fitted a multivariable Cox 
regression model on the nine variables. We expressed each variable's predictive strength by 
its Z-score (model coefficient/standard error). Model coefficients were converted to a risk 
score by multiplying by 10 (for ease of rounding) and summing over all patients.(21) The 
proportionality of hazards (PH) assumption was based on the global PH test.(22)  
 
Prognostic comparisons between models were made by Harrell's concordance c-statistic, a 
summary measure of model accuracy (23) similar to the area under the curve of a receiver-
operator characteristics curve. The validity of the c-statistic is not dependent on parametric 
distribution. A Kaplan-Meier curve was plotted;(24,25) risk groups were compared by the 
log-rank test. An arbitrary level of 5% statistical significance (two-tailed) was assumed. The 
Stata statistical computer package was used to analyse the data (Stata Statistical Software, 
v10, StataCorp, College Station, Texas).  
 
External validation 
We validated our CPET risk score against the more established Heart Failure Survival Score 
(HFSS).(26) The HFSS uses seven variables that independently predict prognosis: peak 
oxygen uptake, resting heart rate (HR), mean blood pressure (mBP), LVEF, serum sodium, 
presence/absence of ischaemic heart disease, presence/absence of an intraventricular 
defect (IVCD). The presence of IVCD was defined as QRS interval ≥120 msec due to left or 
right bundle branch block or ventricular-paced rhythm (irrespective of CRT).(27) 
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Dichotomous variables were coded as 1 = present and 0 = absent. The HFSS was calculated 
in each patient by the following formula:  
HFSS = [(0.0216 x resting HR) + (– 0.0255 x mBP) + (– 0.0464 x LVEF) + (– 0.047 x serum 
sodium) + (– 0.0546 x peak VO2) + (0.608 x presence or absence of IVCD) + (0.6931 x 
presence or absence of ischemic heart disease)].  
 
Results: 
From 423 patients undergoing CPET, we identified 387 patients [median (25
th
-75
th
 
percentile)] (age 65 (56-72) years; 79% males; LVEF 34 (31-37) %; peak VO2 21 (17-25) mL·kg
-
1
·min
-1
; VE/VCO2 slope 32 (29-38) with a complete data set (Table 1). Of these, 70% were 
taking ACE-inhibitors, 72% beta-blockers, and 61% loop diuretics. One hundred and seven 
patients (28%) died during follow-up. The median follow up in survivors was 8.6 ± 2.1 years.  
 
Table 2 shows the inclusion frequencies of the potential variables (P=0.05) from 100 
bootstrapped models. The PH assumption was not violated for any model. Four variables 
appeared in more than one-third of all models (EOV 98%, VE/VCO2 slope 46%, VEqCO2 nadir 
41%, and OUES 34%). The optimal binary cut-points used in our study were as follows: EOV 
(risk score= 10; higher risk threshold = EOV present); VE/VCO2 slope (risk score= 9; higher 
risk threshold >34); VEqCO2 nadir (risk score = 5; higher risk threshold >33); and OUES (risk 
score=5; higher risk threshold <1.8 L·min
-1
). The maximum possible risk score is 29. None of 
our models were over-fitted.(28,29) Prognostic strength ranged from 0.60 to 0.71 (based on 
Harrell’s c-statistic) for individual predictors of mortality. However, prognostic strength 
increased when using a combination of different independent predictors; the optimal 
combination was EOV + VE/VCO2 slope + OUES + VEqCO2 nadir (Harrell’s c-statistic = 0.75).     
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Table 3 shows the distribution of our risk score for all patients and includes observed and 
expected deaths (under the assumption of no relationship between survival and risk score). 
For a risk score of 29 points, there was an excess of deaths in a ratio of 3.8:1. Table 4 shows the 
consistency of the optimal model (EOV + OUES + VEqCO2 nadir + VE/VCO2 slope) when 10 
random samples of 90% of the distribution were re-tested. The number of events in the test 
samples ranged from 90-104. Explained variance for each random model was similar (range 
43%-53%) demonstrating good consistency in the overall model. Table 5 shows changes in 
explained variance for CPET variables when presented as single variables, or in two-way or 
three-way combinations. Explained variance in single CPET variables ranged from 12% - 26%; 
variance increased when CPET variables were considered in two-way combinations (30%-37%); 
and was highest when variables were presented in three-way combinations (36%-43%). For 
example, EOV + VEqCO2 nadir + OUES demonstrated an explained variance of 43% (29-55%). 
This analysis provides further supporting evidence for our 4-variable risk score. Figure 1 shows 
a Kaplan-Meier curve: as the risk score increases, so does the probability of death (log-rank 
test=109.2, df=3, P<0.001).  
 
We explored the goodness-of-fit of our CPET risk score by plotting Cox-Snell residuals against 
the 45
o
 line, and found that the residual plot was closely related (Figure 2). The HR for our risk 
score was 1.10 (95% CI=1.08-1.10; AUC: 0.78; P<0.001). The Hull CPET risk score had a 
significantly higher area under the curve (0.78) when compared to the Heart Failure Survival 
Score (AUC=0.70; P<0.001; Figure 3). 
 
 
Page 10 of 28
http://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Discussion: 
We have shown that a composite risk score using variables from CPET out-performs the 
traditional single variable approach in predicting outcome in patients with mild-to-moderate 
HF. We validated our model against the Heart Failure Survival Score (26) and found that 
variables collected solely from CPET significantly outperformed the well established HFSS. 
The HFSS includes only one CPET-related variable, peak oxygen uptake. The other six 
variables are derived from a combination of standard investigative methods including 
echocardiography, electrocardiography, blood pressure monitoring, blood biochemistry, and 
patient history (aetiology of disease). Recently, Goda and colleagues (27) showed that the 
HFSS outperformed peak oxygen uptake alone for stratifying risk in CHF patients in the 
presence of implantable cardioverter-defibrillators and/or cardiac resynchronisation 
therapy. Risk stratification models should investigate the efficacy of combinations of CPET-
related variables in the era of device therapy.  
 
Historically, most exercise-related composite risk scores have been developed in patients 
with coronary artery disease prior to the widespread adoption of CPET.(5) Perhaps the most 
accepted integrated exercise risk score is the Duke Treadmill Score (DTS) which has both 
prognostic (30) and diagnostic (31) predictive power. The DTS combines exercise time (using 
a Bruce protocol) with ECG abnormalities (ST segment depression) and symptoms of angina. 
It was originally described in patients with coronary artery disease, though successful 
validation in other sub-groups has been reported.(32) Few composite risk score have been 
developed which have specifically included CPET variables for risk stratification among HF 
patients.  
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Risk models using both non-invasive and invasive data (with and without catheterisation 
data) in combination with peak VO2 was developed in 268 patients with advanced HF.(33)  
The models were prospectively validated on 199 similar patients, and the non-invasive 
m del performed well in both samples, and model performance did not improve with the 
addition of invasive catheterisation-related data. The authors concluded that the selection 
of candidates for cardiac transplantation may be improved by using a non-invasive risk-
stratification model which included peak VO2. Myers and colleagues (3) recruited 710 
patients with HF (80% male; 56 ± 13 years; LVEF 33 ± 13 %) from four different institutions 
in Italy and the USA. CPET-derived variables included in the risk score included peak VO2, 
VE/VCO2 slope, OUES, resting PETCO2, heart rate recovery and chronotropic index. The 
VE/VCO2 slope (optimal cut point ≥34) was the strongest predictor of risk and attributed a 
relative weight of 7 points. A cumulative CPET score >15 points was associated with an 
annual mortality of 27% and a relative risk of 7.6. The authors recently published a 
validation study (34) of their original work in a larger sample size using a different statistical 
approach. Our study extends these findings by including other independent predictors of 
mortality in our risk algorithm such as ventilatory variables, EOV and VEqCO2 nadir, and 
circulatory-related variables including heart rate reserve and peak circulatory power.  
 
Guazzi and co-workers (5) used peak VO2, VE/VCO2 slope, EOV, to develop a prognostic risk 
score in 695 patients with heart failure. EOV was the strongest single predictor of cardiac 
mortality. The greatest contribution to the risk score was provided by EOV, followed by 
VE/VCO2 slope, whereas peak VO2 added minimal prognostic value. However, one of the 
major limitations of the study was that it only included 3 variables and did not include other 
potentially important predictive variables such as OUES, VEqCO2 nadir, and peak circulatory 
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power. Recently, Italian clinicians published data from a multi-centre study (34) designed to 
build a new risk score for patients with systolic HF, integrating CPET measures with 
established clinical, laboratory and echocardiographic risk factors in order to identify 
patients at risk of cardiovascular death and urgent heart transplant. The MECKI score 
combined % predicted peak VO2, VE/VCO2 slope, LVEF, haemoglobin, sodium, and 
modification of diet in renal disease. A ROC analysis of the MECKI score for predicting CV 
death and heart transplant was 0.804 at year 1 which decreased to 0.760 by year 4. The 
MECKI score appears to further advance holistic risk models such as the Heart Failure 
Survival Score (26) and the HF-Action Predictive Risk Score Model (35) by the inclusion of a 
well established CPET-related risk algorithm. 
Limitations 
In our study, most patients were men (79%) and further work is needed to validate the risk 
model in women. We only included all-cause mortality as our primary clinical end-point; 
however, this method has advantages over a cardiovascular mortality end-point.(36) We 
accept that dichotomising continuous variables can be problematic; however, we wanted to 
develop a risk score which was simple and easy to use. Using continuous data would mean 
that every variable would have a different score and would require the operator to calculate 
a score per variable and then do a summation. We felt a more pragmatic approach was 
required. We acknowledge that there are many other variables and biomarkers which are 
important predictors of mortality in patients with HF, however, our focus for this risk score 
was solely cardiometabolic variables collected from CPET. 
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Conclusion 
We have found that a composite risk score using four CPET-derived variables (EOV + 
VE/VCO2 slope + OUES + VEqCO2 nadir) out-performs the traditional single variable 
approach in predicting outcome in patients with mild-to-moderate HF. 
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List of Figures 
Figure 1. Kaplan-Meier curve showing risk distribution of the risk score (maximum score = 
29)  
 
Figure 2. Hull CPET survival score: Cox-Snell residual plot  
 
 
Figure 3.  Comparison between the Hull CPET survival score (AUC=0.78, 95%CI=0.72-0.82), 
and  the HFSS (AUC=0.70; 95%CI=0.64-0.75; P<0.001). 
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Table 1. Baseline clinical characteristics in 387 patients with HF [median (25
th
-75
th
 
percentile)] 
Variables All patients 
Age (years) 65 (56-72) 
Males (%) 79 
BMI (kg·m
-2
) 27 (24-30) 
LVEF (%) 34 (31-37) 
Loop diuretic (%) 61 
ACE-I (%) 70 
Beta-blocker (%) 72 
Resting HR (bpm) 75 (64-85) 
FEV1 (% predicted) 90 (76-104) 
Sodium (mmol·L
-1
) 139 (137-141) 
Creatinine (µmol·L
-1
) 104 (86-125) 
Haemoglobin (g/dL
-1
) 13.9 (13.0-15.0) 
Systolic BP (rest, mmHg) 137 (119-152) 
Diastolic BP (rest, mmHg) 84 (73-94) 
DCM (%) 11 
Hypertension (%) 6 
IHD (%) 83 
HR (peak, bpm) 133 (116-155) 
EOV (%) 34 
OUES (L·min
-1
) 1.9 (1.5-2.5) 
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VEqCO2 (nadir) 31.7 (28.0-36.4) 
VE/VCO2 slope 32.1 (28.5-37.8) 
Resting PETCO2 (mmHg) 33.3 (30.2-35.7) 
Peak VO2 (mL·kg
-1
·min
-1
) 21.0 (16.6-25.0) 
AT (mL·kg
-1
·min
-1
) 14.2 (11.4-18.1) 
HRR (beats·min
-1
) 57 (42-77) 
PCP (mmHg·mL
-1
·min
-1
) 3498 (2559-4662) 
Peak RER 1.05 (1.00-1.11) 
Exercise time (seconds) 537 (383 -743) 
Diastolic BP (peak, mmHg) 90 (78-140) 
Systolic BP (peak, mmHg) 171 (150-200) 
QRS duration (m·sec
-1
) 106 (88-128) 
HFSS 9.2 (8.6-9.8) 
DCM: dilated cardiomyopathy; IHD: ischaemic heart disease; EOV: Exertional oscillatory ventilation; OUES: 
oxygen uptake efficiency slope; Resting PETCO2: end-tidal CO2 at rest; AT: anaerobic threshold; HRR: heart rate 
recovery; PCP: peak circulatory power; peak RER: peak respiratory exchange ratio; HR: heart rate; BP: blood 
pressure; HFSS: heart failure survival score. 
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Table 2. An illustration of bootstrapped Cox models for each individual and combined CPET variable(s). An example of models 65 to 100 is 
presented below. 
 
Each column represents one model with the shaded part a variable within the model found to be a predictor of outcome. The frequency with 
which a variable was found from all 100 bootstrapped models is reported as is Harrell’s c-statistic which shows the prognostic strength for 
each individual and combined variable(s). 
 
Variable Bootstrapped models  Frequency C-statistic 
EOV                                     98 0.60 
OUES                                     34 0.70 
VEqCO2 nadir                                     41 0.71 
VE/VCO2 slope                                     46 0.69 
Resting PETCO2                                     9 0.61 
Peak VO2                                     8 0.67 
AT                                     5 0.63 
HRR                                     10 0.64 
PCP                                     18 0.70 
                                       
EOV + OUES                                     -- 0.73 
EOV + VEqCO2 nadir + 
VE/VCO2 slope 
                                    - 0.74 
EOV + OUES + VEqCO2 
nadir + VE/VCO2 slope 
                                    - 0.75 
EOV: Exertional oscillatory ventilation; OUES: oxygen uptake efficiency slope; PETCO2: end-tidal CO2; AT: anaerobic threshold; HRR: heart rate recovery; PCP: peak circulatory power; 
peak RER: peak respiratory exchange ratio.  
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Table 3.  Distribution of the risk score  
 
Risk Score 
 
Frequency Dead Observed (O) Dead Expected (E) O/E ratio 
0 90 7 29.34 0.23 
5 16 1 5.58 0.17 
9 47 6 13.77 0.43 
10 58 12 17.66 0.67 
14 13 3 3.69 0.81 
15 7 1 2.27 0.44 
19 103 39 24.24 1.60 
20 3 2 0.77 2.59 
24 8 6 1.73 3.16 
29 42 30 7.96 3.76 
Total 387 107 107.00  
Chi-squared = 111.9, df=9, P<0.01; Expected cell frequencies based on no association between survival and the risk score. 
 
The risk score is cumulative based on the four most prominent CPET variables we have identified: 
 
If, EOV is present:  risk score= 10;  
VE/VCO2 slope > 34: risk score= 9;  
VEqCO2 nadir >33: risk score = 5;  
OUES <1.8 L·min
-1
 = risk score=5;  
The maximum possible risk score is 29. 
 
Footnote: At each distinct failure-time the contribution to the test statistic comes as a sum of the difference between the observed/expected 
deaths in each of the 10 groups. The expected number of deaths is obtained under a null hypothesis of no differences between the survival 
experiences of the 10 groups. Pearson’s Chi-squared test is calculated as O-E
2
/E.(37)  
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Table 4. Optimal model testing (EOV + OUES + VEqCO2 nadir + VE/VCO2 slope) based on random samples of 90% of the distribution 
 
 
Random sample Events Estimated explained relative risk (%)           
(95% CI) 
1 91 49 (41-64) 
2 96 46 (33-62) 
3 92 43 (28-58) 
4 90 49 (33-65) 
5 94 47 (36-61) 
6 98 50 (35-66) 
7 94 53 (60-66) 
8 102 44 (36-60) 
9 104 46 (32-59) 
10 102 47 (33-65) 
 
 
 
 
 
 
 
Page 20 of 28
http://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
Table 5. Model testing showing changes in estimated explained relative risk in single, two-, and three-way combinations of CPET variables 
 
 
Variable Estimated explained relative risk (%) 
  (95% CI) 
Single variables:  
EOV 12 (5-22) 
VEqCO2 nadir 26 (16-40) 
OUES 22 (12-47) 
VE/VCO2 slope 25 (14-36) 
  
Two-way combinations:  
EOV + VEqCO2 nadir 37 (24-52) 
EOV + OUES 33(19-45) 
EOV + VE/VCO2 slope 35 (20-48) 
VEqCO2 nadir + OUES 33 (22-50) 
VEqCO2 nadir + VE/VCO2 slope 34 (22,50) 
OUES + VE/VCO2 slope 30 (17-46) 
  
Three-way combinations:  
EOV + VEqCO2 nadir + OUES 43 (29-55) 
EOV + VEqCO2 nadir + VE/VCO2 slope 43 (31-58) 
EOV + OUES + VE/VCO2 slope 39 (28-53) 
VEqCO2 nadir + OUES + VE/VCO2 slope 36 (22-50) 
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